Last reviewed · How we verify
AMPHASTAR PHARMS INC — Portfolio Competitive Intelligence Brief
1 marketed
0 filed
0 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Cortrosyn | tetracosactide | marketed | Adrenocorticotropic Hormone [EPC] | Melanocortin receptor 4 | Oncology | 1970-01-01 |
Therapeutic area mix
- Oncology · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- · 1 shared drug class
- Bracco · 1 shared drug class
- Fresenius Kabi · 1 shared drug class
- Guna spa · 1 shared drug class
- Mallinckrodt Ireland · 1 shared drug class
- QUESTCOR PHARMA · 1 shared drug class
- Rad Neurim Pharmaceuticals Eec Sarl · 1 shared drug class
- Sanofi · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for AMPHASTAR PHARMS INC:
- AMPHASTAR PHARMS INC pipeline updates — RSS
- AMPHASTAR PHARMS INC pipeline updates — Atom
- AMPHASTAR PHARMS INC pipeline updates — JSON
Cite this brief
Drug Landscape (2026). AMPHASTAR PHARMS INC — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/amphastar-pharms-inc. Accessed 2026-05-21.